Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€11.50

€11.50

-1.160%
-0.135
-1.160%
-
 
15:38 / Tradegate WKN: A140ML / Name: Novocure / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Financial data and news for Novocure

sharewise wants to provide you with the best news and tools for Novocure, so we directly link to the best financial data sources.

News

Novocure: Steady Ahead of Key Milestones
Novocure: Steady Ahead of Key Milestones

Here's our initial take on Novocure's (NASDAQ: NVCR) fiscal 2025 second-quarter financial report.

Novocure reported no surprises in its latest quarter, with revenue up 6% for the year and both

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025


Novocure (NASDAQ: NVCR) announced today that it will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for unresectable

Novocure to Report Second Quarter 2025 Financial Results
Novocure to Report Second Quarter 2025 Financial Results


Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open.



Novocure management will host a conference call and